Assessing the Clinical Utility of Computed Tomography-Based Radiomics

JULIA LAI-KWON, a SHANKAR SIVA, b, d JEREMY LEWIN a, c, d

Departments of a Cancer Medicine and b Radiation Oncology and ONTrac at Peter Mac Victorian Adolescent & Young Adult Cancer Service, Peter MacCallum Cancer Centre, Parkville, Australia; c Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria, Australia

Disclosures of potential conflicts of interest may be found at the end of this article.

Key Words. Radiomics • Texture metrics • Non-small cell lung cancer • Prognostic

The tumor, node, metastasis (TNM) staging system is the universally accepted process that evaluates disease extent, guides prognosis, and leads to algorithms linked with treatment plans [1]. However, with the emergence of precision medicine, there is increasing need for the development and implementation of integrated models beyond the TNM staging system that may aid clinicians in their decision making. This is particularly important in non-small cell lung cancer (NSCLC) with recent discoveries of actionable mutations in epidermal growth factor receptor (EGFR) mutations, translocations of echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase, and the c-ros oncogene 1 receptor tyrosine kinase, which can be used to guide biomarker-based treatment decisions. As tumors are spatially and temporally heterogeneous, techniques such as biopsies are limited in their ability to characterize tumors in their entirety and are subject to sampling error. Similarly, longitudinal biopsies aimed to assess resistance mechanisms or treatment response are expensive and often impractical or unacceptable to patients. In contrast, medical imaging is a noninvasive and readily repeatable investigation that may provide a more comprehensive understanding of tumor phenotype, allowing monitoring of treatment response and disease progression [2].

Historically, medical images have been described using limited metrics to characterize tumors typically related to size, density or qualitative aspects (e.g., necrotic or cystic change, ground glassing, spiculation). With advances in image acquisition, standardization, and analysis, objective quantitative descriptors or “radiomics” are being investigated to enable interrogation of medical images beyond the limits of visual inspection [2]. The conversion of these images to multidimensional histograms of image intensities can subsequently be mined using bioinformatics tools, measuring properties such as heterogeneity and guide models, which may increase diagnostic, prognostic, and predictive accuracy [3]. The overall hypothesis of this approach is that advanced analysis of standard imaging (such as computed tomography [CT]) can noninvasively augments clinical prognostic nomograms, correlate imaging phenotypes with genomic and proteomic expression, and therefore support clinical decision making.

The scope for using radiomics to guide clinicians in their decision process is considerable. Using this approach has demonstrated independent prognostic and predictive capacities in multiple tumor types, including head and neck, lung, glioblastoma, testicular, and hepatocellular carcinoma [2, 4–6]. Its capacity to quantify intratumoral heterogeneity assists with prognostication, as it is recognized that increased heterogeneity is associated with poorer outcomes and is a significant cause of treatment resistance [7–10]. For example, Aerts et al. demonstrated that a radiomic signature composed of limited features (tumor density, shape, and intratumoral heterogeneity) in NSCLC and head and neck cancers could improve TNM prognostic models [2]. Similarly, CT texture analysis of primary pulmonary lesions in a separate study in NSCLC provided a quantitative assessment of tumor heterogeneity that independently predicted overall survival [8].

Beyond refining prognostication, a radiomics approaches may also generate “imaging biomarkers” that assist in predicting responses to target-drug matching or immunotherapy, as the tumor microenvironment may exhibit distinct radiological features discernible by quantitative imaging metrics. In NSCLC, radiomic features have been used to predict responses to immune therapy as well as immune-related adverse events such as pneumonitis [11]. In addition, a radiomics approach may also help to assess responses to treatment by distinguishing between progression and treatment-related pseudo-progression. In glioblastoma, the use of RECIST criteria to determine treatment response can be challenging. Although specific radiological criteria such as the Response Assessment in Neuro-Oncology criteria have been developed to address this issue [12, 13], textural features on magnetic resonance imaging or positron emission tomography may also assist in discriminating between the two [14, 15].

Within this context, in this issue of The Oncologist, Lee and colleagues sought to address whether radiomic features on preoperative CTs for 339 patients with pathological stage I–III lung adenocarcinoma could be prognostic in addition to baseline clinicopathological features [16]. Lung cancer is particularly...
interesting model to investigate with radiomics, as it is a heterogeneous disease entity with a high somatic mutational burden [17]. Outcomes are poor, particularly in those patients with locally advanced nodal involvement. Thus, there is considerable scope to improve outcomes through discovery of radiological features that may enable judicious selection of disease modifying agents complementary to conventional treatment modalities. The researchers’ key finding was that the integration of 31 selected radiomic features led to better discriminative performance compared with standard TNM variables, with the C-index improving from 0.74 to 0.77. Two radiomic features were significant on multivariate analysis: maximum value of the outer third of the tumor (hazard ratio [HR], 1.001; p = .017), which is thought to represent the tumor microenvironment [18, 19], and size zone variance (HR, 0.998; p = .038), which is thought to measure intratumoral heterogeneity [7–10]. Although this technique is novel and gives unique insight into tumor biology using imaging phenotypes, many questions remain about its clinical translatability. Of note, the hazard ratios for both radiomic features were close to the null value, suggesting that neither was strongly prognostic for overall survival in comparison with conventional clinicopathological variables. This is reflected in the marginal improvement of the C-index of the combined nomogram compared with using standard TNM variables alone. In addition, in clinical practice, minimally invasive or radiological staging is commonly used to inform treatment selection. However, it is recognized that clinically node-negative NSCLC may be pathologically upstaged in 14%–19% of cases [20, 21]. Therefore, it is unclear whether the proposed decision-making model that was built on postoperative pathological findings would remain valid in the preoperative setting.

Although using radiomics is a promising approach, there are still several challenges limiting its routine implementation into clinical practice. First, there is a lack of standardization with regard to image acquisition, reconstruction, and annotation of volumes of interest. Harmonization of quantitative image generation is essential to ensure that future studies are reproducible and data can be shared efficiently between sites [22]. Furthermore, many of these processes, such as contouring volumes of interest, require skill and content expertise that take time to acquire, limiting the rate of uptake into routine practice. Although automated contouring may assist, it is of variable reproducibility depending on the degree of differentiation from neighboring structures such as vessels [23, 24]. Second, radiomics will produce a significant amount of data for each patient. Although correlations between quantitative features and prognosis or treatment outcomes may be able to be obtained statistically, it may be difficult to attribute causality to the radiomic features [3]. External validation of these correlations in independent, prospective, multicenter cohorts or radiomic substudies of ongoing clinical trials will be vital to ensure that models generated from retrospective studies remain robust in the broader population.

Further exploration of the correlation between radiomic features representing the interaction between the tumor and immune infiltrates and responses to immunotherapy is required. The challenges of programmed death-ligand 1 staining as a way of predicting response to immunotherapy in different tumor types have been well documented [25, 26]. Radiomics is well placed as an alternative method of holistically quantifying a tumor’s interaction with immune infiltrates, although further work is required to define the relevant radiomic features. For example, the definition of the outer third of the tumor, and how this is delineated on contouring, remains ambiguous and possibly challenging to reproduce. Although efforts are underway to explore this in the context of metastatic NSCLC, similar techniques may hold promise in selecting patients for adjuvant immunotherapy after definitive chemoradiotherapy in locally advanced disease [27]. This may be particularly relevant as tissue confirmation prior to chemoradiation is typically via needle biopsy, which is prone to sampling error. Similarly, radiomics may also assist in the prediction of response to targeted therapies. Currently, biopsy samples are used to test EGFR mutation status in lung adenocarcinoma. However, variations in mutant DNA allele concentration and intratumoral heterogeneity may lead to false negative results [28–30]. Liu et al. demonstrated that the addition of radiomic features to a pre-existing clinical model resulted in significant improvement in the model’s ability to predict for an EGFR mutation in lung adenocarcinoma [31].

Lastly, incentives are required to address the challenges of standardization, information sharing, and the management of “big data.” This will require a multidisciplinary effort from information technology, radiologists, bioinformaticians, statisticians, and clinicians. In the future, it is envisaged that quantitative data will be routinely extracted from imaging and combined with clinicopathological information to improve the diagnostic accuracy and predictive power of clinical decision-making models. This will help expand radiomics beyond a boutique research area into a clinically useful translational technology.

**DISCLOSURES**

**Shankar Siva:** Janssen Pharmaceuticals, Astellas (C/A), Varian, Astellas, Bristol-Myers Squibb (H), Bristol-Myers Squibb, AstraZeneca (other—travel), Merck Sharp & Dohme, Varian (RF). The other authors indicated no financial relationships.

(C/A) Consulting/advisory relationship; (RF) Research funding; (E) Employment; (ET) Expert testimony; (H) Honoraria received; (OI) Ownership interests; (IP) Intellectual property rights/inventor/patent holder; (SAB) Scientific advisory board

**REFERENCES**

1. Amin MB, Edge S, Greene F et al., eds. AJCC Cancer Staging Manual. 8th ed. Chicago: Springer; 2017.
2. Aerts HJ, Velazquez ER, Leijenaar RT et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 2014;5:4006.
3. Gillies RJ, Kinahan PE, Hricak H. Radiomics: Images are more than pictures, they are data. Radiology 2016;278:563–577.
4. Kuo MD, Gollub J, Sirlin CB et al. Radiogenomic analysis to identify imaging phenotypes associated with drug response gene expression programs in hepatocellular carcinoma. J Vasc Interv Radiol 2007;18:821–831.
5. Gevaert O, Mitchell LA, Achrol AS et al. Glioblastoma multiforme: Exploratory radiogenomic analysis by using quantitative image features. Radiology 2014;273:168–174.
6. Lewin JH, Dufort P, Halankar J et al. Applying radiomics to predict pathology of post chemotherapy retroperitoneal nodal masses in germ cell tumors (GCT). J Clin Oncol 2017;35(suppl 15):4559A.
7. Sequist LV, Waltman BA, Dias-Santagata D et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3:75ra26.
8. Ganeshan B, Panayiotou E, Burnand K et al. Tumour heterogeneity in non-small cell lung
carcinoma assessed by CT texture analysis: A potential marker of survival. Eur Radiol 2012;22:796–802.

9. Tixier F, Le Rest CC, Hatt M et al. Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J Nucl Med 2011;52:369–378.

10. Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 2013;501:346–354.

11. Colen RR, Fujii T, Bilen MA et al. Radiomics to predict immunotherapy-induced pneumonitis: Proof of concept. Invest New Drugs 2017 [Epub ahead of print].

12. Ellingson BM, Wen PY, Cloughesy TF. Modified criteria for radiographic response assessment in glioblastoma clinical trials. Neurotherapeutics 2017;14:307–320.

13. Kucharczyk MJ, Parpia S, Whitton A et al. Evaluation of pseudoprogression in patients with glioblastoma. Neurooncol Pract 2017;4:120–134.

14. Lohmann P, Lerche C, Stoffels G et al. P09.26 PET radiomics - diagnosis of pseudoprogression in glioblastoma patients based on textural features. Neuro Oncol 2017;19(suppl 3):ii75.

15. Abrol S, Kotrotsou A, Hassan A et al. Radiomic analysis of pseudo-progression compared to true progression in glioblastoma patients: A large-scale multi-institutional study. J Clin Oncol 2017;35(suppl 15):2015A.

16. Lee G, Park H, Sohn I et al. Comprehensive computed tomography radiomics analysis of lung adenocarcinoma for prognostication. The Oncologist 2018 [Epub ahead of print].

17. Alexandrov LB, Nik-Zainal S, Wedge DC et al. Signatures of mutational processes in human cancer. Nature 2013;500:415–421.

18. Miecznik B, Bindea G, Kirilovsky A et al. The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis. Sci Transl Med 2016;8:327ra26.

19. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011;144:646–674.

20. Boffa DJ, Kosinski AS, Paul S et al. Lymph node evaluation by open or video-assisted approaches in 11,500 anatomic lung cancer resections. Ann Thorac Surg 2012;94:347–353.

21. Licht PB, Jørgensen OD, Ladegaard L et al. A national study of nodal upstaging after thoracoscopic versus open lobectomy for clinical stage I lung cancer. Ann Thorac Surg 2013;96:943–949.

22. Siu LL, Lawler M, Haussler D et al. Facilitating a culture of responsible and effective sharing of cancer genome data. Nat Med 2016;22:464–471.

23. Kumar V, Gu Y, Basu S et al. Radiomics: The process and the challenges. Magn Reson Imaging 2012;30:1234–1248.

24. Parmar C, Rios Velazquez E, Leijenaar R et al. Robust radiomics feature quantification using semi-automatic volumetric segmentation. PLoS One 2014;9:e102107.

25. Hansen AR, Siu LL. PD-L1 testing in cancer: Challenges in companion diagnostic development. JAMA Oncol 2016;2:15–16.

26. Tao M, Kerr K, Yatabe Y et al. PL 03.03 Blue-print 2: PD-L1 immunohistochemistry comparability study in real-life, clinical samples. J Thoracic Oncol 12(suppl 2):S1506.

27. Antonia SJ, Villegas A, Daniel D et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 2017;377:1919–1929.

28. Shahi RB, De Brakeeleer S, De Grève J et al. Detection of EGFR-TK domain-activating mutations in NSCLC with generic PCR-based methods. Appl Immunohistochem Mol Morphol 2015;23:163–171.

29. Tomonaga N, Nakamura Y, Yamaguchi H et al. Analysis of intratumor heterogeneity of EGFR mutations in mixed type lung adenocarcinoma. Clin Lung Cancer 2013;14:521–526.

30. Taniguchi K, Okami J, Kodama K et al. Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci 2008;99:929–935.

31. Liu Y, Kim J, Balagurunathan Y et al. Radiomic features are associated with EGFR mutation status in lung adenocarcinomas. Clin Lung Cancer 2016;17:441–448.e6.